C2C Wealth Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

C2C Wealth Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,715	Closed	-$478K	–	96
2026 Q1	$478K	Hold	1,715	–	–	0.4%	47
2025 Q4	$520K	Hold	1,715	–	–	0.44%	46
2025 Q3	$481K	Hold	1,715	–	–	0.41%	47
2025 Q2	$414K	Hold	1,715	–	–	0.37%	52
2025 Q1	$418K	Hold	1,715	–	–	0.39%	52
2024 Q4	$563K	Sell	1,715 -10	-0.6%	-$3.39K	0.52%	42
2024 Q3	$618K	Hold	1,725	–	–	0.58%	42
2024 Q2	$471K	Hold	1,725	–	–	0.46%	45
2024 Q1	$597K	Hold	1,725	–	–	0.59%	40
2023 Q4	$560K	Hold	1,725	–	–	0.47%	51
2023 Q3	$606K	Hold	1,725	–	–	0.09%	120
2023 Q2	$674K	Hold	1,725	–	–	0.09%	121
2023 Q1	$824K	Hold	1,725	–	–	0.13%	97
2022 Q4	$780K	Hold	1,725	–	–	0.14%	73
2022 Q3	$775K	Hold	1,725	–	–	0.15%	74
2022 Q2	$845K	Hold	1,725	–	–	0.15%	74
2022 Q1	$957K	Hold	1,725	–	–	0.16%	77
2021 Q4	$1.3M	Buy	+1,725	New	+$1.29M	0.19%	68

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

C2C Wealth Management's BIO Position: Q2 2026 in Review

C2C Wealth Management sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2026, closing a stake of 1,715 shares — an estimated $478K sold.

C2C Wealth Management first reported a position in BIO in Q4 2021 and held it in 18 quarters. The position peaked at $1.3M in Q4 2021. 399 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

C2C Wealth Management reported no remaining Bio-Rad Laboratories Class A position as of Q2 2026 after selling out during the quarter.
C2C Wealth Management sold 1,715 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $478K.
C2C Wealth Management first reported a position in Bio-Rad Laboratories Class A in Q4 2021 and held it in 18 quarters.
C2C Wealth Management's Bio-Rad Laboratories Class A position peaked at $1.3M in Q4 2021.
399 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on C2C Wealth Management's 13F filing for Q2 2026, filed 9 Jul 2026.